Core Insights - WuXi Vaccines has received Good Manufacturing Practices (GMP) certification from Brazil's ANVISA for its fill and finish facility in Suzhou, marking a significant regulatory milestone for the company [1] - The facility will support the production of Instituto Butantan's dengue vaccine, aiming to deliver several million doses to enhance public health in Brazil [1] - The partnership with Instituto Butantan includes comprehensive manufacturing services, emphasizing WuXi Vaccines' commitment to quality and accessibility in vaccine production [1] Company Overview - WuXi Vaccines is a wholly-owned subsidiary of WuXi Biologics, specializing in vaccine Contract Development and Manufacturing Organization (CDMO) services [1] - The company offers integrated development and manufacturing platforms for various vaccine modalities, including recombinant protein and viral vectored vaccines [1] - With extensive GMP manufacturing capabilities and regulatory expertise, WuXi Vaccines plays a crucial role in expediting vaccine delivery to the market [1]
WuXi Vaccines Receives Brazil's ANVISA GMP Certification
Prnewswire·2026-02-12 03:48